利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.029 秒)

    Reshaped human antibody to human medulloblastoma cells
    1.
    发明授权
    Reshaped human antibody to human medulloblastoma cells 失效
    人成神经管细胞瘤细胞的人源化抗体

    公开(公告)号：US07563599B2

    公开(公告)日：2009-07-21

    申请号：US10839799

    申请日：2004-05-06

    申请人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    发明人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    IPC分类号： C12P21/04 ,  C07H21/04 ,  C12P21/08 ,  C07K16/00

    CPC分类号： C07K16/3053 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

    摘要： The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

    摘要翻译： 本发明公开了对人成神经管细胞瘤细胞重整的抗体，其包含：（A）L链，其包含：（1）人L链C区，和（2）包含人L链FR和L链CDR的L链V区 单克隆抗体ONS-M21给人成神经管细胞瘤细胞; 和（B）包含以下物质的H链：（1）人H链C区，和（2）包含人H链FR的H链V区和小鼠单克隆抗体ONS-M21的H链CDR至人成神经管细胞瘤细胞。 由于这种重构的人抗体的大部分来自人抗体，小鼠CDR具有低水平的抗原性，所以本发明的重构人（人源化）抗体在人中具有低水平的抗原性，因此预期为 可用作用于脑肿瘤如成神经管细胞瘤的治疗剂和诊断工具，其能强烈表达被该抗体识别的抗原。

    Reshaped human antibody to human medulloblastoma cells
    4.
    发明申请
    Reshaped human antibody to human medulloblastoma cells 失效
    人成神经管细胞瘤细胞的人源化抗体

    公开(公告)号：US20050249726A1

    公开(公告)日：2005-11-10

    申请号：US10839799

    申请日：2004-05-06

    申请人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    发明人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    IPC分类号： A61K38/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/30 ,  C07K16/44 ,  C12N5/06 ,  C12P21/06 ,  C12P21/08

    CPC分类号： C07K16/3053 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

    摘要： The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

    摘要翻译： 本发明公开了对人成神经管细胞瘤细胞重整的抗体，其包含：（A）L链，其包含：（1）人L链C区，和（2）包含人L链FR和L链CDR的L链V区 单克隆抗体ONS-M21给人成神经管细胞瘤细胞; 和（B）包含以下物质的H链：（1）人H链C区，和（2）包含人H链FR的H链V区和小鼠单克隆抗体ONS-M21的H链CDR至人成神经管细胞瘤细胞。 由于这种重构的人抗体的大部分来自人抗体，小鼠CDR具有低水平的抗原性，所以本发明的重构人（人源化）抗体在人中具有低水平的抗原性，因此预期为 可用作用于脑肿瘤如成神经管细胞瘤的治疗剂和诊断工具，其能强烈表达被该抗体识别的抗原。

    Reshaped human antibody to human interleukin-8
    5.
    发明授权
    Reshaped human antibody to human interleukin-8 有权
    重组人抗人白介素-8抗体

    公开(公告)号：US06245894B1

    公开(公告)日：2001-06-12

    申请号：US09416557

    申请日：1999-10-12

    申请人： Kouji Matsushima ,  Yoshihiro Matsumoto ,  Yoshiki Yamada ,  Koh Sato ,  Masayuki Tsuchiya ,  Tatsumi Yamazaki

    发明人： Kouji Matsushima ,  Yoshihiro Matsumoto ,  Yoshiki Yamada ,  Koh Sato ,  Masayuki Tsuchiya ,  Tatsumi Yamazaki

    IPC分类号： C07K1400

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2319/00

    摘要： A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

    摘要翻译： 重整的人抗体的特征在于具有与嵌合抗体相同的IL-8的结合亲和力，但相比之下具有低的免疫原性。 重构抗体具有以下元件：来自针对人IL-8和人H链C区或人H链FR的小鼠单克隆抗体的人L链C区或人L链FR和L链CDR， 小鼠单克隆抗体针对人IL-8的H链CDR。 由于重整人抗体对人的免疫原性低，因此适用于各种医疗条件的医疗。

    Reshaped human antibody to human interleukin-6
    6.
    发明授权
    Reshaped human antibody to human interleukin-6 失效
    人类白细胞介素-6重组人抗体

    公开(公告)号：US06121423A

    公开(公告)日：2000-09-19

    申请号：US205231

    申请日：1998-12-04

    申请人： Masayuki Tsuchiya ,  Koh Sato ,  Yuichi Hirata

    发明人： Masayuki Tsuchiya ,  Koh Sato ,  Yuichi Hirata

    IPC分类号： C07K16/00 ,  C07K16/24 ,  C12P21/08

    CPC分类号： C07K16/00 ,  C07K16/248 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2319/00

    摘要： A reshaped antibody comprising:(A) L chains comprising:(1) a human C region, and(2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and(B) H chains comprising:(1) a human H chain C region, and(2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.

    摘要翻译： 重组抗体，其包含：（A）L链，其包含：（1）人C区，和（2）包含小鼠单克隆抗体的人L链FR和L链CDR的L链V区; 和（B）H链，其包含：（1）人H链C区，和（2）包含人H链FR的H链V区和针对人IL-6的小鼠单克隆抗体的H链CDR。 由于重构人抗体的主要部分来自人，小鼠CDR的免疫原性较小，因此本发明的重组人抗体免疫原性较小，因此抑制IL-6的信息传递，并且作为治疗剂是有希望的 IL-6引起的疾病。

    Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
    9.
    发明授权
    Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody 有权
    针对人组织因子（TF）的人源化抗体和人源化抗体的生产过程

    公开(公告)号：US07494647B2

    公开(公告)日：2009-02-24

    申请号：US10462062

    申请日：2003-06-16

    申请人： Koh Sato ,  Hideki Adachi ,  Naohiro Yabuta

    发明人： Koh Sato ,  Hideki Adachi ,  Naohiro Yabuta

    IPC分类号： A61K39/395

    CPC分类号： C07K16/36 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2319/00

    摘要： A humanized antibody against tissue factor (TF), comprising:A: a humanized H chain comprising (1) a H chain V region comprising the H chain CDRs of a mouse monoclonal antibody against TF and the H chain FRs of a human antibody, and (2) the H chain C region of a human antibody; andB: a humanized L chain comprising (1) an L chain V region comprising the L chain CDRs of a mouse monoclonal antibody against TF and the L chain FRs of a human antibody, and (2) the L chain C region of a human antibody.After generating a humanized V region by grafting the CDRs of a mouse monoclonal antibody onto a human antibody, a humanized antibody having a higher activity is searched by replacing the FR of the above region with the corresponding FR of the human antibody having a high homology.

    摘要翻译： 一种抗组织因子（TF）的人源化抗体，包括：A：人源化H链，其包含（1）H链V区，其包含针对TF的小鼠单克隆抗体的H链CDR和人抗体的H链FR，以及 （2）人抗体的H链C区; 和B：人源化L链，其包含（1）包含针对TF的小鼠单克隆抗体的L链CDR和人抗体的L链FR的L链V区，和（2）人的L链C区 抗体。 通过将小鼠单克隆抗体的CDR移植到人抗体上产生人源化V区后，通过用具有高同源性的人抗体的相应FR代替上述区域的FR来搜索具有较高活性的人源化抗体。

    Reshaped human antibody to human interleukin-6 receptor
    10.
    发明授权
    Reshaped human antibody to human interleukin-6 receptor 失效
    重组人抗人白细胞介素-6受体

    公开(公告)号：US07479543B2

    公开(公告)日：2009-01-20

    申请号：US10837904

    申请日：2004-05-04

    申请人： Masayuki Tsuchiya ,  Koh Sato ,  Mary Margaret Bendig ,  Steven Tarran Jones ,  Jose William Saldanha

    发明人： Masayuki Tsuchiya ,  Koh Sato ,  Mary Margaret Bendig ,  Steven Tarran Jones ,  Jose William Saldanha

    IPC分类号： C07K16/00

    CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K2317/24 ,  C07K2319/00

    摘要： A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.

    摘要翻译： 对人IL-6R的重构人抗体包含：（A）包含（1）人L链C区的L链，和（2）包含人L链框架区（FR）的L链V区， 和IL-6受体（IL-6R）的单克隆抗体的小鼠L链互补决定区（CDR）; 和（B）包含（1）人H链C区和（2）包含人H链FRS的H链V区的H链和与IL-6R的单克隆抗体的小鼠H链CDR。 由于重构的人抗体的大部分衍生自人抗体和免疫原性较小的小鼠CDR，所以本发明的重组人抗体对人的免疫原性较低，因此被用于治疗用途。